" class="no-js "lang="en-US"> Sandra Thiollière - Medtech Alert
Friday, August 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Sandra Thiollière

Sandra Thiollière

About Sandra Thiollière

Passionate about technologies related to medicine, I chose to direct my career as an INSA Lyon Engineer towards the Medical Devices industry. My various experiences from SMEs to international groups have allowed me to acquire a very global vision of activities related to this sector and to develop a solid experience in Quality.

Related Story

Diseases

 Carthera Receives FDA Breakthrough Device Designation for SonoCloud-9 System | Pharmtech Focus

Carthera Receives FDA Breakthrough Device Designation for SonoCloud-9 System

June 22 2022

Carthera, a French company that designs and develops SonoCloud, an innovative ultrasound-based medical device to […]